<?xml version="1.0" encoding="UTF-8" ?>
<?xml-stylesheet type="text/xsl" href="https://blogs.mercola.com:443/utility/FeedStylesheets/rss.xsl" media="screen"?><rss version="2.0" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:slash="http://purl.org/rss/1.0/modules/slash/" xmlns:wfw="http://wellformedweb.org/CommentAPI/"><channel><xhtml:meta xmlns:xhtml="http://www.w3.org/1999/xhtml" name="robots" content="noindex" /><title>Pfizer's New Game Plan to Promote Celebrex</title><link>https://blogs.mercola.com:443/sites/vitalvotes/archive/2005/02/23/Pfizers-New-Game-Plan-to-Promote-Celebrex.aspx</link><description>Shortly after Merck's Vioxx was pulled from the consumer market in this country, rival Pifzer announced a bold, but ultimately failed, move to bolster Celebrex's marketshare: A study to determine if the COX-2 inhibitor could prevent heart attacks. Two</description><dc:language>en</dc:language><generator>CommunityServer 2008.5 SP1 (Debug Build: 31106.3070)</generator></channel></rss>